Olaparib in ovarian cancer with BRCA mutation

被引：5

作者：

Pujade-Lauraine, Eric ^{[1
]}

Combe, Pierre ^{[2
]}

机构：

[1] GH Paris Ctr, Ctr Canc Femme & Rech Clin, F-75181 Paris 04, France

[2] Hop Europeen Georges Pompidou, Serv Oncol Med, F-75015 Paris, France

来源：

BULLETIN DU CANCER | 2015年 / 102卷 / 06期

关键词：

BRCA; Ovarian cancer; Olaparib; PARP;

D O I：

10.1016/S0007-4551(15)31221-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

With 4500 new cases and 3200 death each year, ovarian cancer is the first cause of mortality for gynecological cancer in France. Without any efficient screening, it is usually diagnosed around the age of 60 years at an advanced stage. The emergence of olaparib, a new targeted therapy, represents a major opportunity.

引用

页码：S82 / S84

页数：3

共 2 条

[1] Hereditary ovarian carcinomas: clinico-biological features and treatment
Floquet, Anne
Stoeckle, Eberhard
Croce, Sabrina
Longy, Michel
Mc Grogan, Gaetan
Barouk, Emmanuelle
Bubien, Virginie
Garbay, Delphine
Joly, Eglantine
Guyon, Frederic
[J]. BULLETIN DU CANCER, 2014, 101 (02) : 167 - 174
[2] Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Ledermann, Jonathan
Harter, Philipp
Gourley, Charlie
Friedlander, Michael
Vergote, Ignace
Rustin, Gordon
Scott, Clare L.
Meier, Werner
Shapira-Frommer, Ronnie
Safra, Tamar
Matei, Daniela
Fielding, Anitra
Spencer, Stuart
Dougherty, Brian
Orr, Maria
Hodgson, Darren
Barrett, J. Carl
Matulonis, Ursula
[J]. LANCET ONCOLOGY, 2014, 15 (08) : 852 - 861

← 1 →